LOS ANGELES, Feb. 9 /PRNewswire/ -- BBK Worldwide, patient recruitment leader and clinical research and development consultancy, announces the opening of a West Coast office in Los Angeles. This expansion is a response to increasing demands from biotechnology/biopharmaceutical research sponsors for worldwide coverage to successfully meet recruitment deadlines. Building on the 2009 office opening of BBK Worldwide - Osaka in Japan, and adding to BBK's existing global alliance network and Boston, London, and Prague locations, the Los Angeles office creates an opportunity for BBK to better serve clients in the Pacific time zone. [more]
CARY, N.C.--(BUSINESS WIRE)--Feb 8, 2010 - Industry Standard Research (ISR Reports) today announced the launch of a substantial research report titled Success in Patient and Investigator Recruitment. This report presents data and analysis from 362 interviews with Patients, Principal Investigators, and Drug development professionals from around the world. [more]
HORSHAM, Pa.--(BUSINESS WIRE)--Feb 8, 2010 - Acurian, Inc., a leading, full-service provider of patient recruitment and retention solutions, announced today that its patient recruitment database now contains over 65 million records, or 49% of the estimated 133 million Americans with a chronic disease. [more]
LONDON, Feb. 8, 2010--Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials supports the recent call to include more elderly people in clinical trials. Synexus’ Dedicated Recruitment Centres across the UK and overseas, have been successfully recruiting older people to their trials for some time now and are keen to see this trend continue. [more]
RALEIGH, N.C. – Tom Sturgis, president of ICTS (www.icts.us), has announced that the company has completed the development and implementation of a physician communication program to assist in enrollment for two global flu treatment studies. ICTS (Integrated Clinical Trial Services, LLC) is a strategic clinical trials support company that utilizes more than 300 contract employees internationally. ICTS’ unique, protocol-driven, acute study solution assists in providing enrollment communication assistance via a secure, multi-lingual Internet portal. [more]
ROCHESTER, Minn., Feb. 5 /PRNewswire/ -- Centerphase has entered into a collaboration with Mayo Clinic to speed the introduction of new medical treatments developed by the biopharmaceutical industry. The Company addressed the root causes historically plaguing the clinical trials process: the lack of a systematic, structured approach for evaluating and optimizing protocols and the tremendous burdens associated with trial start-up administration. [more]
NEWTOWN, PA, February 4, 2010 – BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services, has signed a three-year, multi-million dollar deal with Cephalon, Inc. for clinical trial technology and support services. As part of the Service Agreement, US-based data management staff at Cephalon will be hired by BioClinica to support clinical efforts of Cephalon. [more]
NEWTOWN, Pa.--(BUSINESS WIRE)--Feb 4, 2010 - BioClinica, Inc., a leading global provider of clinical trial services, has signed a three-year, multi-million dollar deal with Cephalon, Inc. for clinical trial technology and support services. [more]
COLUMBIA, Mo.--(BUSINESS WIRE)--Feb 4, 2010 - Recognizing an increased industry need for outsourced biopharmaceutical drug development services, Analytical Bio-Chemistry Laboratories (ABC) has expanded its offering to include comprehensive support for large molecule development. [more]
Durham, NC: February 3, 2010) Health Decisions (www.HealthDec.com), a full-service clinical research organization (CRO) specializing in high-efficiency adaptive solutions, has completed enrollment for a Phase II universal flu vaccine study only three weeks after the first site initiation visit and less than three months after the partnership was contracted. If the candidate is proven effective, millions of flu vaccine doses could be produced in a time frame of weeks instead of months, a breakthrough with major positive implications for global populations threatened by seasonal and pandemic influenza strains like the H1N1 Swine Flu. [more]
Rheinbach, Germany, February 2, 2010 / b3c newswire / - clinicalprojects international GmbH (CPI), an independent contract research organization, announced today that the company is continuing its growth into new therapeutic areas for the development of (bio)pharmaceuticals and medical devices. [more]
London, February 2, 2010 – ClearTrial (www.cleartrial.com), the leading provider of Clinical Trial Operations (CTO) software, today announced that it will be demonstrating the software's capabilities to drive greater outsourcing efficiency to an audience of more than 125 clinical outsourcing professionals at the 3rd Annual Clinical Outsourcing World conference in London. The event attracts biopharmaceutical companies from around the globe to hear top clinical outsourcing experts discuss major strategic and operational challenges of partnering with clinical research organizations (CROs). [more]
West Lebanon, NH – February 1, 2010 – M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials announced that the company doubled its clinical trials business from December 2008 to December 2009. At the close of 2009, M2S was managing trials across multiple therapeutic areas, including vascular device, oncology, musculoskeletal and osteoporosis. The trials ranged from Phase I to Phase III for the biopharmaceutical industry and from first-in-man to pivotal within the device trials. [more]
WILMINGTON, N.C.--(BUSINESS WIRE)--Feb 2, 2010 - PPD, Inc. today announced it is celebrating 25 years as one of the world's leading contract research organizations, building upon its strong foundation and history of helping clients deliver safe, effective medicines to patients. [more]
CLEVELAND, Feb. 1 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the contract signing for a Phase IV, eight-year, 500-site, 5,000-patient study worth approximately $900,000 with a global specialty pharmaceutical and medication delivery company. This non-interventional, multi-center study will be deployed internationally utilizing DATATRAK eClinical(TM) for the observation of treatment of Renal Anemia. [more]
TORONTO, Feb. 1 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced successful completion of its recent Health Canada audit. [more]
BANGALORE, India, Feb. 1 /CNW/ - Infinitus Clinical Research is continuing to pioneer its unique strategy. This is based on the following elements: [more]
New York, (January 28, 2010) – Clinilabs, a contract research organization (CRO) specializing in early phase and specialty studies, is proud to announce that the Company has formed a collaboration with the Renal Research Institute, LLC (RRI), with headquarters in New York. This collaboration allows Clinilabs and the RRI to provide a high level of clinical drug development services to pharmaceutical and biotechnology companies. The collaboration includes Spectra Clinical Research, a division of Spectra Laboratories, the leading provider of renal-specific testing services in the United States. [more]
MATTAWAN, Mich.--(BUSINESS WIRE)--Jan 29, 2010 - On January 26, 2010, the FDA released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA's current position on the abuse potential of drugs. [more]
RESEARCH TRIANGLE PARK, N.C. & MELVILLE, N.Y. January 28, 2010 -- -- Novella Clinical Inc. (formerly PharmaLinkFHI) and OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Companies will expand their existing clinical service agreement. [more]
Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook
This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.
The introductory rate of $395 expires February 17, 2010.
